A pilot study of @entity3003 ( @entity17327 , @entity3003 ) and @entity5805 in combination for advanced XXXX .

@entity1 @entity43 @entity137 @entity390 @entity882 @entity5 @entity3003 @entity391 @entity900 @entity5805 @entity17327 @entity1210
Forty-six @entity1 with previously untreated, advanced @entity43 received @entity3003 ( @entity17327 , @entity3003 ) and @entity5805 (CLB) to assess the efficacy and @entity137 of this combination. @entity3003 300 mg m-2 was given on day 1 with CLB 10 mg daily for 7, 10 or 14 days; 6 treatment courses were given at 4-6 weekly intervals in the absence of disease progression. @entity5 response was assessed, where possible, by restaging laparotomy after 6 treatment cycles. Five complete and 16 partial remission were seen in 37 evaluable @entity1 giving an overall response rate of 57%. The median survival of all @entity1 was 15 months. The major @entity137 was myelosuppression. @entity390 and @entity391 were generally minor (WHO, grades I or II) and most courses were given on an outpatient basis. @entity1210 was the major factor causing treatment delays, particularly with the 10 and 14 day CLB regimens. @entity882 was minimal in the early chemotherapy cycles but the data suggest that cumulative @entity137 may occur. This combination may provide a satisfactory degree of efficacy with less @entity137 than @entity900 -based regimens.
